Status:

COMPLETED

Alefacept Mechanism of Action in Psoriasis

Lead Sponsor:

University of Medicine and Dentistry of New Jersey

Collaborating Sponsors:

Biogen

Conditions:

Psoriasis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

To determine the mechanism of action of alefacept in patients with psoriasis.

Detailed Description

The purpose of the study is to better understand the mechanism of action of an FDA approved drug (alefacept). Subjects enrolled will be given alefacept 7.5 mg intravenously on a weekly basis for 12 we...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Alefacept is indicated for the treatment of adult patients (18 years or older) with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. Patients must have at least one plaque of least 2.5 cm in diameter (for biopsies).
  • Exclusion Criteria
  • CD4 \< 400/ml
  • WBC less than lower level of normal for the reporting laboratory
  • \< 5% Body Surface Area involved with psoriasis
  • Serious infection e.g., latent or active tuberculosis
  • History of AIDS or Hepatitis B,C, all internal cancers, lymphoma, untreated cutaneous basal or squamous cell carcinoma
  • Systemic anti-psoriasis medications and phototherapy within 28 days of the first dose of Alefacept
  • Topical anti-psoriasis medications within 14 days of the first dose of Alefacept, except for moisturizers, tar shampoos (exception, Elidel is permitted to be applied on the face, groin and axillae areas. These areas are not biopsied.)
  • Inability to understand consent form or comply with study requirements
  • Pregnancy or lactation
  • Concurrent medical illness that would make participation in this clinical trial ill-advised
  • Any contraindications to using alefacept

Exclusion

    Key Trial Info

    Start Date :

    September 1 2003

    Trial Type :

    INTERVENTIONAL

    End Date :

    February 1 2005

    Estimated Enrollment :

    9 Patients enrolled

    Trial Details

    Trial ID

    NCT00150982

    Start Date

    September 1 2003

    End Date

    February 1 2005

    Last Update

    August 7 2008

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UMDNJ Clinical Research Center

    New Brunswick, New Jersey, United States, 08903